Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 135

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 135
---
 an actual basis; |

| • |     | on a pro forma basis to reflect (i) the conversion of all outstanding shares of our redeemable convertible                                                                                                                              
 preferred stock into 78,072,306 shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to stockholders’ equity upon the closing of this offering, and (ii) the 
 filing of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and                                                                                                                  |

| • |     | on a pro forma as adjusted basis to reflect (i) the pro forma adjustments set forth above and (ii) our                                                                                                        
 issuance and sale of      shares of common stock in this offering at the assumed initial public offering price of $   per share, which is the midpoint of the price range set forth on the cover page of this 
 prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.                                                                                         |

The pro forma and pro forma as adjusted information below is illustrative only, and our cash and cash equivalents and marketable securities and capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our audited financial statements and the related notes included elsewhere in this prospectus and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other financial information contained in this prospectus.

|                                                                                                                   |     | (Unaudited)                                       
 As of June 30, 2025                               |         |     |           |   |     |             |   |
|:------------------------------------------------------------------------------------------------------------------|:----|:--------------------------------------------------|--------:|:----|:----------|:--|:----|:------------|:--|
|                                                                                                                   |     | Actual                                            |         |     | Pro Forma |   |     | Pro Forma   
 As Adjusted |   |
|                                                                                                                   |     | -in thousands, except share and per share amounts |         |     |           |   |     |             |   |
| Cash and cash equivalents                                                                                         |     | $                                                 |  14,225 |     | $         |   |     | $           |   |
| Derivative liability – warrants                                                                                   |     | $                                                 |   1,925 |     |           |   |     |